AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
August 08, 2024 | 9:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.
The discontinuation of the EBO-301 study is a significant negative development for AN2 Therapeutics, as it indicates a setback in their clinical pipeline. This has led to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100